



Clinical trial results:

A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U

Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2014-002654-39 |
| Trial protocol | NL BE |
| Global end of trial date | 21 December 2021 |

Results information

| | |
|--------------------------------|------------------|
| Result version number | v1 (current) |
| This version publication date | 17 December 2022 |
| First version publication date | 17 December 2022 |

Trial information

Trial identification

| | |
|-----------------------|-------|
| Sponsor protocol code | HO130 |
|-----------------------|-------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | HOVON |
| Sponsor organisation address | De Boelelaan 1117, Amsterdam, Netherlands, |
| Public contact | HOVON Data Center, HOVON, +31 0107041560, hdc@erasmusmc.nl |
| Scientific contact | HOVON Data Center, HOVON, +31 0107041560, hdc@erasmusmc.nl |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|-------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 26 September 2019 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 19 June 2019 |
| Global end of trial reached? | Yes |
| Global end of trial date | 21 December 2021 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To evaluate the efficacy of the combination of lenalidomide and R-CHOP in MYC+ DLBCL patients in terms of CR rate by end-of-treatment 18F-FDG PET-CT scan and BM.

Protection of trial subjects:

Monitoring and Insurance

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 25 February 2015 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-----------------|
| Country: Number of subjects enrolled | Netherlands: 83 |
| Country: Number of subjects enrolled | Belgium: 2 |
| Worldwide total number of subjects | 85 |
| EEA total number of subjects | 85 |

Notes:

Subjects enrolled per age group

| | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 1 |
| Adults (18-64 years) | 45 |
| From 65 to 84 years | 39 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

All subjects gave written informed consent and were screened according to the inclusion- and exclusion criteria

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Arms

| | |
|------------------|--------------------|
| Arm title | Experimental Group |
|------------------|--------------------|

Arm description: -

| | |
|--|---------------|
| Arm type | Experimental |
| Investigational medicinal product name | Lenalidomide |
| Investigational medicinal product code | |
| Other name | Revlimib |
| Pharmaceutical forms | Capsule, hard |
| Routes of administration | Oral use |

Dosage and administration details:

15mg, day 1 - 14.

| | |
|--|--------------------|
| Investigational medicinal product name | Cyclophosphamide |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection/infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

750mg/m2 on day 1.

| | |
|--|-----------------|
| Investigational medicinal product name | Vincristine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

1.4 mg/m2 (max 2mg) on day 1

| | |
|--|-----------------|
| Investigational medicinal product name | Doxorubicin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

50mg/m2 on day 1

| | |
|--|-----------|
| Investigational medicinal product name | Rituximab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |

| | |
|--|------------------|
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| 375 mg/m ² on day 1 | |
| Investigational medicinal product name | Prednisone |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| 100mg on day 1-5 | |
| Investigational medicinal product name | Pegfilgrastim |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 6mg on day 2 | |

| Number of subjects in period 1 | Experimental Group |
|--------------------------------|--------------------|
| Started | 85 |
| Completed | 72 |
| Not completed | 13 |
| Adverse reactions | 2 |
| Other | 3 |
| At patient's request | 1 |
| Lack of efficacy | 7 |

Baseline characteristics

Reporting groups

Reporting group title

Overall trial

Reporting group description: -

| Reporting group values | Overall trial | Total | |
|---|---------------|-------|--|
| Number of subjects | 85 | 85 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 1 | 1 | |
| Adults (18-64 years) | 45 | 45 | |
| From 65-84 years | 39 | 39 | |
| 85 years and over | 0 | 0 | |
| Age continuous | | | |
| Units: years | | | |
| median | 63 | | |
| full range (min-max) | 29 to 82 | - | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 27 | 27 | |
| Male | 58 | 58 | |

End points

End points reporting groups

| | |
|--------------------------------|--------------------|
| Reporting group title | Experimental Group |
| Reporting group description: - | |

Primary: Primary Endpoint

| | |
|------------------------|---------------------------------|
| End point title | Primary Endpoint ^[1] |
| End point description: | |

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

See publication.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: See attached chart/documents for results.

| | | | | |
|-----------------------------|--------------------|--|--|--|
| End point values | Experimental Group | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 82 | | | |
| Units: Whole | 82 | | | |

| | |
|-----------------------------------|---|
| Attachments (see zip file) | Statistical data section from publication/HO130 Statistical data List of reported non-SAE's/nonsaedata130-30Nov2022.pdf List of reported SAE's/saedata130-30Nov2022.pdf |
|-----------------------------------|---|

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events will be reported from the first study-related procedure until 30 days following the last dose of any drug from the protocol treatment schedule or until the start of subsequent systemic therapy for the disease under study, if earlier.

Adverse event reporting additional description:

Adverse events occurring after 30 days should also be reported if considered at least possibly related to the investigational medicinal product by the investigator.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|-------|
| Dictionary name | CTCAE |
|-----------------|-------|

| | |
|--------------------|---|
| Dictionary version | 4 |
|--------------------|---|

Reporting groups

| | |
|-----------------------|--------------------|
| Reporting group title | Experimental Group |
|-----------------------|--------------------|

Reporting group description: -

| Serious adverse events | Experimental Group | | |
|---|--|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 37 / 85 (43.53%) | | |
| number of deaths (all causes) | 29 | | |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Additional description: All combined, see SAE chart for details. | | |
| subjects affected / exposed | 7 / 85 (8.24%) | | |
| occurrences causally related to treatment / all | 4 / 7 | | |
| deaths causally related to treatment / all | 1 / 1 | | |
| Vascular disorders | | | |
| Vascular disorders | Additional description: All combined, see SAE chart for details. | | |
| subjects affected / exposed | 1 / 85 (1.18%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Surgical and medical procedures | | | |
| Surgical and medical procedures | Additional description: All combined, see SAE chart for details. | | |
| subjects affected / exposed | 1 / 85 (1.18%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General disorders and administration | | | |

| | | | |
|--|--|--|--|
| site conditions | | | |
| General disorders and administration site conditions | Additional description: All combined, see SAE chart for details. | | |
| subjects affected / exposed | 8 / 85 (9.41%) | | |
| occurrences causally related to treatment / all | 5 / 9 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Respiratory, thoracic and mediastinal disorders | Additional description: All combined, see SAE chart for details. | | |
| subjects affected / exposed | 2 / 85 (2.35%) | | |
| occurrences causally related to treatment / all | 2 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Investigations | | | |
| Investigations | Additional description: All combined, see SAE chart for details. | | |
| subjects affected / exposed | 1 / 85 (1.18%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Injury, poisoning and procedural complications | | | |
| Injury, poisoning and procedural complications | Additional description: All combined, see SAE chart for details. | | |
| subjects affected / exposed | 1 / 85 (1.18%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac disorders | | | |
| Cardiac disorders | Additional description: All combined, see SAE chart for details. | | |
| subjects affected / exposed | 4 / 85 (4.71%) | | |
| occurrences causally related to treatment / all | 2 / 4 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nervous system disorders | | | |
| Nervous system disorders | Additional description: All combined, see SAE chart for details. | | |
| subjects affected / exposed | 4 / 85 (4.71%) | | |
| occurrences causally related to treatment / all | 0 / 4 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Blood and lymphatic system disorders | | | |
| Blood and lymphatic system disorders | Additional description: All combined, see SAE chart for details. | | |

| | | | |
|---|--|--|--|
| subjects affected / exposed | 8 / 85 (9.41%) | | |
| occurrences causally related to treatment / all | 9 / 9 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |
| Gastrointestinal disorders | Additional description: All combined, see SAE chart for details. | | |
| subjects affected / exposed | 11 / 85 (12.94%) | | |
| occurrences causally related to treatment / all | 8 / 14 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal and urinary disorders | | | |
| Renal and urinary disorders | Additional description: All combined, see SAE chart for details. | | |
| subjects affected / exposed | 2 / 85 (2.35%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Musculoskeletal and connective tissue disorders | Additional description: All combined, see SAE chart for details. | | |
| subjects affected / exposed | 1 / 85 (1.18%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Infections and infestations | Additional description: All combined, see SAE chart for details. | | |
| subjects affected / exposed | 12 / 85 (14.12%) | | |
| occurrences causally related to treatment / all | 13 / 16 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Metabolism and nutrition disorders | | | |
| Metabolism and nutrition disorders | Additional description: All combined, see SAE chart for details. | | |
| subjects affected / exposed | 1 / 85 (1.18%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 0 %

| | | | |
|---|--|--|--|
| Non-serious adverse events | Experimental Group | | |
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 71 / 85 (83.53%) | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Additional description: All combined, see non-SAE chart for details. | | |
| subjects affected / exposed | 1 / 85 (1.18%) | | |
| occurrences (all) | 1 | | |
| Vascular disorders | | | |
| Vascular disorders | Additional description: All combined, see non-SAE chart for details. | | |
| subjects affected / exposed | 10 / 85 (11.76%) | | |
| occurrences (all) | 13 | | |
| Surgical and medical procedures | | | |
| Surgical and medical procedures | Additional description: All combined, see non-SAE chart for details. | | |
| subjects affected / exposed | 1 / 85 (1.18%) | | |
| occurrences (all) | 1 | | |
| General disorders and administration site conditions | | | |
| General disorders and administration site conditions | Additional description: All combined, see non-SAE chart for details. | | |
| subjects affected / exposed | 10 / 85 (11.76%) | | |
| occurrences (all) | 16 | | |
| Reproductive system and breast disorders | | | |
| Reproductive system and breast disorders | Additional description: All combined, see non-SAE chart for details. | | |
| subjects affected / exposed | 1 / 85 (1.18%) | | |
| occurrences (all) | 1 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Respiratory, thoracic and mediastinal disorders | Additional description: All combined, see non-SAE chart for details. | | |
| subjects affected / exposed | 8 / 85 (9.41%) | | |
| occurrences (all) | 9 | | |
| Psychiatric disorders | | | |
| Psychiatric disorders | Additional description: All combined, see non-SAE chart for details. | | |
| subjects affected / exposed | 1 / 85 (1.18%) | | |
| occurrences (all) | 1 | | |
| Investigations | | | |
| Investigations | Additional description: All combined, see non-SAE chart for details. | | |
| subjects affected / exposed | 20 / 85 (23.53%) | | |
| occurrences (all) | 63 | | |

| | | | |
|---|--|--|--|
| Cardiac disorders | | | |
| Cardiac disorders | Additional description: All combined, see non-SAE chart for details. | | |
| subjects affected / exposed | 7 / 85 (8.24%) | | |
| occurrences (all) | 8 | | |
| Nervous system disorders | | | |
| Nervous system disorders | Additional description: All combined, see non-SAE chart for details. | | |
| subjects affected / exposed | 33 / 85 (38.82%) | | |
| occurrences (all) | 38 | | |
| Blood and lymphatic system disorders | | | |
| Blood and lymphatic system disorders | Additional description: All combined, see non-SAE chart for details. | | |
| subjects affected / exposed | 11 / 85 (12.94%) | | |
| occurrences (all) | 19 | | |
| Ear and labyrinth disorders | | | |
| Ear and labyrinth disorders | Additional description: All combined, see non-SAE chart for details. | | |
| subjects affected / exposed | 5 / 85 (5.88%) | | |
| occurrences (all) | 5 | | |
| Eye disorders | | | |
| Eye disorders | Additional description: All combined, see non-SAE chart for details. | | |
| subjects affected / exposed | 3 / 85 (3.53%) | | |
| occurrences (all) | 3 | | |
| Gastrointestinal disorders | | | |
| Gastrointestinal disorders | Additional description: All combined, see non-SAE chart for details. | | |
| subjects affected / exposed | 24 / 85 (28.24%) | | |
| occurrences (all) | 33 | | |
| Hepatobiliary disorders | | | |
| Hepatobiliary disorders | Additional description: All combined, see non-SAE chart for details. | | |
| subjects affected / exposed | 1 / 85 (1.18%) | | |
| occurrences (all) | 1 | | |
| Skin and subcutaneous tissue disorders | | | |
| Skin and subcutaneous tissue disorders | Additional description: All combined, see non-SAE chart for details. | | |
| subjects affected / exposed | 6 / 85 (7.06%) | | |
| occurrences (all) | 6 | | |
| Renal and urinary disorders | | | |
| Renal and urinary disorders | Additional description: All combined, see non-SAE chart for details. | | |
| subjects affected / exposed | 5 / 85 (5.88%) | | |
| occurrences (all) | 5 | | |
| Musculoskeletal and connective tissue disorders | | | |

| | | | |
|--|--|--|--|
| Musculoskeletal and connective tissue disorders subjects affected / exposed occurrences (all) | Additional description: All combined, see non-SAE chart for details. | | |
| | 8 / 85 (9.41%) 10 | | |
| Infections and infestations Infections and infestations subjects affected / exposed occurrences (all) | Additional description: All combined, see non-SAE chart for details. | | |
| | 24 / 85 (28.24%) 32 | | |
| Metabolism and nutrition disorders Metabolism and nutrition disorders subjects affected / exposed occurrences (all) | Additional description: All combined, see non-SAE chart for details. | | |
| | 10 / 85 (11.76%) 13 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|----------------|--|
| 23 June 2015 | Clarification in sections 9 and 10 in the protocol. |
| 17 August 2016 | Updates in section 4 and clarifications in section 8, 10 and 17 of the protocol. |
| 18 July 2017 | Target number of patients has been increased. Updates in section 4, 5, 6, clarifications in section 8, 9 , 10 and updates in section 14, 19 appendix B1 and B2. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported